NFKB1 and familial pancreatic carcinoma: To further determine whether the enhanced sensitivity to gemcitabine after Bmi1 inhibition is correlated with the changes of NF-κB activity in pancreatic cancer cells, we compared the status of NF-κB in pancreatic cancer cells through EMSA.